Aromatase expression in the tumour parenchyma and stroma has been found significantly associated with more than a 2-fold risk of bladder cancer recurrence and may be associated with advanced tumour stage and poorer survival outcomes (112), while aromatase in the tumour stroma was significantly associated to adverse pathologic variables and poorer overall survival (113). Here, CYP19A1 is linked to urinary bladder cancer.